Home
NewsNewsINVO Fertility partners with Heidi Health to integrate an AI-powered scribe at Wisconsin Fertility Institute, streamlining documentation so clinicians focus on care.
INVO Fertility, a healthcare fertility company committed to expanding access to advanced treatment through clinic operations and technological innovation, has announced a strategic alliance with Heidi Health to deploy its AI-powered scribe platform at the Wisconsin Fertility Institute (WFI).
The collaboration marks a key step in INVO Fertility’s efforts to enhance clinical efficiency and patient care through digital transformation. Heidi Health’s AI-driven platform is built by doctors and integrates seamlessly with existing EHR systems, allowing providers to automate documentation without overhauling their digital infrastructure. By adapting to each physician’s preferred note-taking style, the system generates precise and personalized clinical documentation, cutting down administrative time and cognitive strain for medical teams.
The system currently supports nearly 2 million patient interactions each week and is used in more than 50 countries, in over 200 specialties, and across more than 110 languages. “We’re thrilled to collaborate with INVO Fertility and WFI to bring our AI-driven tools to Wisconsin patients,” said Dr. Thomas Kelly, CEO and co-founder of Heidi Health. “Heidi’s AI scribe automates an average of over two hours of daily administrative work, transcribing and processing clinician-patient conversations, producing clinical notes and follow-up materials so clinicians can focus on delivering quality care to their patients.”
For fertility specialists at INVO’s Wisconsin Fertility Institute, the integration of Heidi AI Scribe will mean the automation of patient consultation transcription, creating accurate records, case histories, and administrative files in real time. This efficiency is particularly crucial in reproductive medicine, where providers manage both the emotional and medical complexity of infertility care. The technology is expected to reduce manual note-taking by as much as 80%, enabling doctors to engage more meaningfully with patients, strengthen trust, and refine individualized treatment plans.
Dr. Gretchen Collins, medical director and Reproductive Endocrinologist and Infertility specialist at the Wisconsin Fertility Institute, shared her enthusiasm for the initiative. “We are excited to be partnering with Heidi Health to find ways to continually elevate the patient experience at our Wisconsin clinic, ensuring every individual feels supported each step of the way. This technology empowers our team to focus on what matters most – building families.”
According to Steve Shum, CEO of INVO Fertility, the move continues the company’s trajectory toward innovation and patient-first care. “This partnership builds on INVO Fertility’s series of recent advancements to bring cutting-edge technology and advanced treatment options to our Wisconsin-based facility,” he stated. “Moving forward, we will continually look at new ways to ensure we achieve our mission to empower families with the tools and expertise they need to achieve their dreams of parenthood.”
By leveraging Heidi Health’s AI-powered scribe technology, INVO Fertility aims to streamline documentation while preserving the empathy and attention that define fertility care. The partnership underscores a shared vision of using intelligent automation to enhance clinical efficiency and deepen patient engagement a milestone in INVO Fertility’s mission to redefine accessibility and experience in reproductive healthcare.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
